BULLETIN DU CANCER癌症通报
BULLETIN DU CANCER(英文缩写 B CANCER),ISSN 0007-4551,eISSN 1769-6917,中文译名:癌症通报 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 1.318 | Q4 |
| 2022 | 1.200 | Q4 |
| 2023 | 1.100 | Q4 |
| 2024 | 0.800 | Q4 |
| 2025 | 1.100 | Q4 |
BULLETIN DU CANCER 最新收录文献
-
1. [Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].
PMID:日期:2026-10-01Genetic counseling and molecular tumor boards have become essential components of oncology care pathways. Since 2012, a private-sector oncogenetics program supported by the National Cancer Institute (INCa), has been established within the Hauts-de-Seine health cooperation group, in connection with partner laboratories and a dedicated molecular tumor board. The study includes 10,071 oncogenetic consultations carried out between 2013 and 2024, and 1012 patients who underwent circulating tumor DNA (ctDNA) analysis between 2020 and 2024. Results were discussed in molecular and oncogenetic tumor boards. The median delay for a first consultation was 3 weeks, compared to 10 weeks nationally. Mutation detection rates in hereditary breast-ovarian syndromes ranged from 11 to 16%, higher than the national average (8.8%). Among the 1012 ctDNA-tested patients, 411 (40%) presented actionable tumor alterations, including 284 (28%) classified as ESCAT I. Additional constitutional testing was triggered in 112 patients, revealing 27 unsuspected pathogenic variants (2.7%). Private-practice oncogenetics and molecular tumor boards can achieve performance comparable to national indicators in terms of delays and mutation detection. The coordination between constitutional and tumor genetics activities enhances both therapeutic decisions and familial risk assessment.
-
2. Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies.
PMID:日期:2026-10-01Triple-negative breast cancer (TNBC) remains a highly aggressive and therapeutically challenging subtype, defined by the absence of oestrogen, progesterone, and HER2 expression. Tumour Protein 53 (TP53) mutations represent the most frequent genetic alteration, occurring in over 80% of cases and driving tumour initiation, progression, and therapeutic resistance. Mutant p53 proteins not only lose canonical tumour-suppressive functions but also often acquire gain-of-function (GOF) oncogenic properties that promote metastasis, genomic instability, and resistance to mechanisms like ferroptosis. This review examines the biological role of TP53 in TNBC pathogenesis and evaluates emerging pharmacological strategies aimed at targeting these vulnerabilities. Key approaches include the pharmacological reactivation of mutant p53 using small molecules such as APR-246, COTI-2, and the mutation-specific reactivator rezatapopt (PC14586), which has shown significant clinical tumour reduction in Y220C-mutant patients. Other strategies involve targeted protein degradation, the exploitation of synthetic lethal interactions (e.g., Chk1 or Aurora kinase B inhibition), and the use of natural products like cryptolepine or piperine derivatives. Recent clinical evidence further highlights the potential of combining epigenetic agents like decitabine with chemotherapy in TP53-mutant populations. Integrating TP53 mutation status into biomarker-driven treatment paradigms is a pivotal step toward achieving precision oncology and improving clinical outcomes for patients with TNBC.
-
3. [Regional survey of the feelings of cancer patients included in a clinical trial].
PMID:日期:2026-10-01该文献暂无摘要。
-
5. [When models encounter clinical reality: Artificial intelligence in oncology practice].
PMID:日期:2026-10-01该文献暂无摘要。
-
6. [Who refer patients with multiple myeloma to hematology-oncology: A retrospective study at Hôtel-Dieu de France].
PMID:日期:2026-10-01Multiple myeloma presents with a wide spectrum of symptoms that may initially direct patients to different medical specialties. This study aims to identify the specialties that most frequently refer newly diagnosed patients to hemato-oncology. A retrospective study was conducted using the medical records of adult patients diagnosed with multiple myeloma at the Hôtel-Dieu de France University Hospital between 2013 and 2024. Collected data included the referring specialty, age, sex, isotypes, percentage of bone marrow plasma cells, prognostic factors, the Revised International Staging System, initial symptoms, and therapeutic modalities. Two hundred patients were included, comprising 120 men and 80 women, with a median age at diagnosis of 68 and 64 years, respectively. Among patients referred by a specialty (88%), orthopedic surgeons were the main referring physicians (19.3%), followed by nephrologists (17.6%), rheumatologists (10.2%), and cardiologists (8.5%). Patients referred by surgical specialties were more frequently diagnosed at an early stage I (P<0.001), whereas those referred by medical specialties more often presented with stage II or III disease. Multiple myeloma is frequently diagnosed outside hemato-oncology. The predominance of orthopedic referrals reflects the high frequency of bone involvement, favoring earlier diagnosis. In contrast, medical specialties are associated with more advanced stages, related to later systemic manifestations. This highlights the importance of clinical vigilance and multidisciplinary collaboration to improve early detection.
-
8. Use of bevacizumab to treat glioblastoma in France: Regional practices in PACA and Corsica show a real therapeutic need.
PMID:日期:2026-10-01Glioblastomas, the most common and aggressive brain tumors in adults, present a significant therapeutic challenge. Despite the limited treatment options outlined by current guidelines, bevacizumab has emerged as a critical, yet controversial option. This study investigates the off-label use of bevacizumab in France, highlighting its therapeutic demand despite the absence of marketing authorization. Since the European Medicines Agency (EMA) rejected its application for glioblastoma treatment in 2009, it has not been re-evaluated at the European level. This research primarily aims to explore clinical practices surrounding bevacizumab's use and assess its relevance and potential benefits for patients with glioblastoma in real-world settings. A cross-sectional, observational epidemiological survey was conducted using data from ScanSanté® and feedback from hospitals in the Provence-Alpes-Côte d'Azur (PACA) and Corsica regions. These findings were then compared to literature data. In 2023, bevacizumab was used in 97.3% of hospital days related to malignant brain tumors treated off-label in France. Among off-label prescriptions for glioblastomas, 82.0% were for recurrent glioblastomas, 13.1% for newly diagnosed glioblastomas, and 4.9% had no precise diagnosis. Literature reviews indicate a favorable benefit-risk balance for certain patient profiles, particularly showing improved progression-free survival and quality of life when bevacizumab is employed. The significant off-label use of bevacizumab in glioblastoma treatment underscores an urgent therapeutic need in France. These findings were submitted to the French National Agency for the Safety of Medicines and Health Products (ANSM) to advocate for its regulated use in clinical practice.
-
9. [GFCO national recommendations on the use of liquid biopsy for circulating tumor DNA analysis in oncology].
PMID:日期:2026-10-01The analysis of circulating tumor DNA (ctDNA) by liquid biopsy is a major advance in the management of patients with cancer, offering a minimally invasive method for detecting tumor genetic alterations and enabling personalized monitoring. Faced with complex technological challenges and the need for rigorous validation, the French-Speaking Group for Oncological Cytogenomics (GFCO) has established national consensus guidelines. These guidelines, designed to govern ctDNA analysis, were developed using the Delphi consensus methodology. A questionnaire developed by a working group of eight biologists and two bioinformaticians was submitted to 55 French platforms specializing in liquid biopsy in oncology. A participation rate of 71% was achieved. Consensus was defined by an agreement threshold of at least 80%. A live discussion and voting session was held during the GFCO 2024 Days for items that did not initially reach this threshold. The validated recommendations cover the pre-analytical, analytical, and post-analytical phases. In total, 37 recommendations with a consensus exceeding 80% were adopted. These GFCO recommendations provide a standardized framework for the use of liquid biopsy in oncology in France. Regular updates will be necessary to adapt to the rapid evolution of the technology.
-
10. Regulated cell death pathways in endocrine tumor plasticity: A narrative review.
PMID:日期:2026-10-01Endocrine tumors arise from highly differentiated hormone-secreting cells and are characterized by strong hormone dependence, high metabolic activity, and marked phenotypic plasticity. During tumor progression and therapeutic intervention, endocrine tumor cells can adapt to adverse microenvironmental conditions and treatment pressure through remodeling of differentiation states, reprogramming of signaling pathways, and metabolic adaptation. Regulated cell death (RCD) is a key determinant of cell fate and an important mediator of anticancer treatment responses, while also being closely linked to tumor plasticity. In this review, we summarize the major forms of RCD in endocrine tumors and their crosstalk, with a focus on how hormone and metabolic signaling shape the RCD network and influence tumor plasticity. Current evidence suggests that endocrine signals, nutrient-sensing pathways, and organ-specific metabolic stress regulate multiple forms of RCD, including apoptosis, ferroptosis, autophagy-dependent cell death, and inflammatory cell death, thereby influencing the death threshold of tumor cells and contributing to therapy resistance, dedifferentiation, and invasive behavior. We also discuss emerging therapeutic strategies targeting RCD, as well as potential biomarkers and clinical stratification approaches. A better understanding of the interaction between RCD and endocrine tumor plasticity may help shift the current therapeutic concept from simply inducing tumor cell death to limiting maladaptive plasticity, thus offering new opportunities to overcome therapeutic resistance and dedifferentiation.